ALPELISIB (PIQRAY)
PIK3CA-MUTATED BREAST CANCER
Alpelisib specifically inhibits PI3Kα — the mutant PI3K isoform that drives oestrogen-independent signalling in PIK3CA-mutated breast cancer. Added to fulvestrant, it nearly doubles progression-free survival — but requires active management of hyperglycaemia, which occurs in over 65% of patients.
analyticsAt a Glance
- check_circlePIK3CA is mutated in 40% of ER+/HER2− breast cancers — making alpelisib relevant to a substantial patient population
- check_circleSOLAR-1 trial: alpelisib + fulvestrant improved median PFS from 5.7 to 11.0 months in PIK3CA-mutant subgroup
- check_circleHyperglycaemia is the primary dose-limiting toxicity — mandatory metformin co-prescription and glucose monitoring are required
- check_circleLiquid biopsy or tissue NGS is required to confirm PIK3CA mutation before alpelisib prescription
The PI3K Pathway in ER-Positive Breast Cancer and Why PIK3CA Mutation Matters
The PI3K/AKT/mTOR pathway is one of the most frequently altered signalling cascades in breast cancer — activated by growth factor receptors, including the oestrogen receptor, to drive cell survival and proliferation. PIK3CA — the gene encoding the catalytic subunit of PI3Kα (PI3K alpha) — is mutated in approximately 40% of ER+/HER2− breast cancers. These mutations constitutively activate PI3K signalling, driving oestrogen-independent cell growth and contributing to endocrine resistance.
“PIK3CA mutation is one of the most common oncogenic events in ER+ breast cancer — and the most specifically targetable. Alpelisib was designed from the outset to inhibit only the PI3Kα isoform encoded by PIK3CA, sparing the other PI3K isoforms that regulate insulin signalling — though hyperglycaemia still occurs because PI3Kα has a role in insulin action.”
How PIK3CA Mutation Drives Endocrine Resistance
In ER+ breast cancer, oestrogen activates the oestrogen receptor, which activates PI3K signalling as a downstream growth stimulus. When PIK3CA is mutated, PI3K is constitutively active — providing a growth signal independently of oestrogen. This means the cancer can continue to grow even when aromatase inhibitors or tamoxifen remove the oestrogen stimulus, contributing to endocrine resistance.
Why Alpelisib Is PI3Kα-Selective
There are four PI3K isoforms (α, β, γ, δ). Earlier pan-PI3K inhibitors caused severe diarrhoea and immune suppression by inhibiting all four isoforms. Alpelisib specifically inhibits PI3Kα — the isoform encoded by the mutant PIK3CA — which reduces off-target toxicity while maintaining on-target efficacy in PIK3CA-mutant tumours. Hyperglycaemia still occurs because PI3Kα mediates insulin signalling in the liver and muscle, but the other isoform-related toxicities are substantially reduced.
The SOLAR-1 Trial: Key Results for PIK3CA-Mutant Breast Cancer
SOLAR-1 is the Phase III trial that established alpelisib as a standard-of-care option for PIK3CA-mutant ER+/HER2− metastatic breast cancer after progression on endocrine therapy.
SOLAR-1: PFS by PIK3CA Mutation Status — Alpelisib + Fulvestrant vs Fulvestrant
Source: André F et al., N Engl J Med. 2019;380(20):1929–1940. All patients had prior endocrine therapy.
- Median PFS: Alpelisib + fulvestrant (PIK3CA-mutant)11.0 mo
- Median PFS: Fulvestrant alone (PIK3CA-mutant)5.7 mo
- Median PFS: Alpelisib + fulvestrant (PIK3CA-wild-type)7.4 mo
- Median PFS: Fulvestrant alone (PIK3CA-wild-type)5.6 mo
PIK3CA Mutation Testing: How, When, and What to Look For
PIK3CA mutation must be confirmed before alpelisib can be prescribed. Testing options and their practical considerations are outlined below.
| Testing Method | Specimen | Key Mutations Detected | Practical Notes |
|---|---|---|---|
| ctDNA liquid biopsy (Guardant360, Foundation Liquid, Tempus xF) | Blood — 10 mL EDTA tube | All PIK3CA hotspot mutations: E545K, H1047R, E542K, and others | Preferred at metastatic progression — detects all lesions; rapid turnaround 7–14 days; approved companion diagnostic for alpelisib (Guardant360 CDx in US) |
| Tissue NGS (Foundation One, MSK-IMPACT, local NGS panel) | Archival FFPE tissue block or new biopsy | All PIK3CA mutations plus co-alterations (ESR1, PTEN, AKT1) | Archival primary tumour tissue is acceptable — PIK3CA mutations are usually clonal and present in primary. New biopsy captures any acquired mutations. Turnaround 2–4 weeks |
| Targeted PIK3CA hotspot PCR assay | Blood or tissue | Most common hotspots (E545K, H1047R, E542K) | Lower sensitivity than NGS — may miss uncommon mutations; not recommended as primary testing method |
| therascreen PIK3CA RGQ PCR Kit | Plasma (blood) | Major PIK3CA hotspots — FDA-approved companion diagnostic alongside Guardant360 CDx | US FDA-approved companion diagnostic; available in some Asian markets |
Hyperglycaemia Management: The Critical Side Effect of Alpelisib
Hyperglycaemia is the most important management challenge with alpelisib — occurring in >65% of patients to any grade and in ~36% at Grade 3–4. Without proactive management, it leads to treatment discontinuation in many patients.
| Parameter | Guidance | Notes |
|---|---|---|
| Baseline fasting glucose | Must be <126 mg/dL (7.0 mmol/L) before starting alpelisib | Do not start alpelisib in patients with uncontrolled diabetes or baseline glucose ≥126 mg/dL without diabetologist review first |
| HbA1c at baseline | HbA1c <8% (64 mmol/mol) required; optimise glycaemic control before start if elevated | Pre-existing diabetes does not exclude alpelisib — but requires close metabolic management |
| Mandatory metformin | Metformin 500 mg BD starting with or before first alpelisib dose — regardless of pre-existing diabetes | Metformin reduces alpelisib-related hyperglycaemia by ~30% — mandatory co-prescription; no contraindication if eGFR >30 mL/min |
| Glucose monitoring | Fasting glucose at baseline, Day 8, Day 15, Week 4, then monthly; more frequently if any hyperglycaemia | Patient should have glucometer at home; educate on symptoms of hyperglycaemia: thirst, polyuria, fatigue |
| Grade 1 hyperglycaemia (>ULN–250 mg/dL / 10–13.9 mmol/L) | Continue alpelisib; optimise metformin (increase to 1000 mg BD if tolerated); dietary low-carbohydrate counselling | Low-glycaemic-index diet significantly reduces glucose excursions on alpelisib |
| Grade 2 (251–500 mg/dL / 13.9–27.8 mmol/L) | Hold alpelisib; continue metformin; add short-acting insulin or SGLT-2 inhibitor; consult endocrinologist | Restart at same dose if resolved to Grade ≤1 within 7 days; reduce to 250 mg if recurs |
| Grade 3–4 (>500 mg/dL / >27.8 mmol/L) | Hold alpelisib; initiate IV insulin if Grade 4 or symptomatic; urgent endocrinology review | Restart at 200 mg after Grade 3 resolution; permanent discontinuation considered for recurrent Grade 4 |
| Pre-existing diabetic patients | Continue existing diabetes medications + mandatory metformin; more frequent glucose monitoring; earlier endocrinology co-management | HbA1c <8% required before starting; close collaboration between oncologist and endocrinologist throughout |
Benefits vs Limitations of Alpelisib in Clinical Practice
Alpelisib offers a meaningful targeted therapy option for a specific molecular subgroup — but its toxicity profile requires active management and appropriate patient selection.
Benefits
- Significant PFS benefit in PIK3CA-mutant subgroup5.3-month improvement in median PFS (11.0 vs 5.7 months) — a clinically meaningful benefit in a heavily pretreated population with limited endocrine options.
- Addresses a targetable molecular alterationPIK3CA mutation (present in 40% of ER+ breast cancers) is a specific, testable, and targetable event — making alpelisib a precision medicine approach in this subgroup.
- No benefit in PIK3CA-wild-type — saves non-candidates from toxicityThe absence of benefit in PIK3CA-wild-type patients means that molecular testing spares patients without the target from a high-toxicity drug that would not help them.
- Oral once-daily tablet300 mg once daily with food — manageable outpatient regimen if hyperglycaemia is proactively addressed.
Limitations
- Hyperglycaemia in >65% of patients — high management burdenRequires metformin, glucose monitoring, dietary counselling, and frequent blood tests — a significant ongoing management burden that requires patient engagement and oncology-endocrinology collaboration.
- Severe rash in 15–20%Maculopapular or bullous rash requiring dose hold or reduction — managed with antihistamines and topical or systemic corticosteroids, but can limit tolerability.
- Diarrhoea in 25–30%Managed with loperamide and dietary modification; less severe than pan-PI3K inhibitors but still requires proactive management.
- Grade 3–4 hyperglycaemia in ~36%The frequency of high-grade hyperglycaemia remains a significant treatment barrier — patients with pre-existing metabolic syndrome or diabetes require particularly close management.
More from the Hormone Therapy Resource Library
Continue exploring targeted therapies for advanced ER+ breast cancer.
- CDK4/6 Inhibitors: Palbociclib, Ribociclib, Abemaciclib Explained
- Fulvestrant and Elacestrant: SERDs Explained
- ESR1 Mutations in Breast Cancer: What They Mean and How They Change Treatment
- ER, PR, and HER2 Status Explained: What the Results Mean
- Aromatase Inhibitors: Letrozole, Anastrozole, and Exemestane
- Hormone Therapy for Breast Cancer — Complete Guide
Frequently Asked Questions
Common questions from patients considering or taking alpelisib.
About Alpelisib and PIK3CA Mutation
I have diabetes — does this mean I cannot take alpelisib?
Pre-existing diabetes is not an absolute contraindication to alpelisib, but it requires careful preparation and close management. Before starting: your HbA1c must be below 8% (64 mmol/mol) — if it is higher, your diabetes must be optimised first. During treatment: metformin is mandatory, blood glucose monitoring is more frequent, and early endocrinology co-management is strongly recommended. Patients with well-controlled diabetes on oral hypoglycaemics often manage alpelisib-related hyperglycaemia with metformin + their existing medication with dose adjustments. Patients on insulin need careful titration. This is a discussion to have with both your oncologist and diabetologist — not a reason to automatically decline alpelisib if PIK3CA mutation is confirmed and the benefit is established.
What should I eat when taking alpelisib to help control my blood sugar?
Diet plays a meaningful role in managing alpelisib-related hyperglycaemia. A low-glycaemic-index, low-refined-carbohydrate diet substantially reduces blood glucose excursions after meals. Specifically: avoid white bread, white rice, sugary drinks, sweets, and processed carbohydrates; prefer whole grains, vegetables, legumes, lean protein, and healthy fats; eat smaller, more frequent meals rather than large carbohydrate-heavy meals; and do not skip meals, as hypoglycaemia (if on diabetes medications) is also a risk. Your oncology team should refer you to a dietitian at alpelisib initiation — this is not an optional consultation, it is a practical component of tolerability management.
My tumour showed H1047R PIK3CA mutation — is this responsive to alpelisib?
Yes — H1047R is one of the most common PIK3CA mutations (accounting for ~25–35% of all PIK3CA mutations in breast cancer) and is fully responsive to alpelisib. It is located in the kinase domain of PI3Kα and constitutively activates the enzyme's catalytic activity. H1047R was well-represented in the SOLAR-1 trial population and the benefit in PIK3CA-mutant patients applies to all major PIK3CA mutation subtypes including H1047R, E545K, and E542K. If your testing has confirmed H1047R and you meet the other eligibility criteria for alpelisib (ER+/HER2−, prior endocrine therapy, metastatic disease), discuss alpelisib + fulvestrant as your next treatment line with your oncologist.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Does Your Cancer Have a PIK3CA Mutation?
CancerFax can arrange PIK3CA mutation testing through liquid biopsy or tissue NGS, and connect you with specialist oncologists who can assess whether alpelisib combined with fulvestrant is appropriate for your current disease status and metabolic profile.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.